Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Caroline Arber; Gabriela Baerlocher; Yves Chalandon; Michael Daskalakis; Michel Duchosal; Martin Fehr; Sabine Gerull; Tayfun Güngör; Gayathri Nair; Thomas Pabst; Jakob R. Passweg; Barbara Piccolruaz; Christoph Renner; Axel Ruefer; Dominik Schneidawind; Georg Stüssi; Sacha Zeerleder; Jörg P. Halter

doi:10.57187/s.3704

Technical comment

Vol. 154 No. 10 (2024)

Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Caroline Arber⁺⁻
Gabriela Baerlocher
Yves Chalandon
Michael Daskalakis
Michel Duchosal
Martin Fehr
Sabine Gerull
Tayfun Güngör
Gayathri Nair
Thomas Pabst
Jakob R. Passweg
Barbara Piccolruaz
Christoph Renner
Axel Ruefer
Dominik Schneidawind
Georg Stüssi
Sacha Zeerleder
Jörg P. Halter

Cite this as:: Swiss Med Wkly. 2024;154:3704
Published: 03.10.2024

Summary

No abstract available.

References

Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2023 Sep;153(9):3441. doi: https://doi.org/10.57187/s.3441
Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol. 2024 Jan;42(1):e3241. doi: https://doi.org/10.1002/hon.3241
Duchosal MA, et al. Développements récents en hématologie, Teil 1. Swiss Medical Forum, 2023. doi: https://doi.org/10.4414/fms.2023.09462
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56. doi: https://doi.org/10.1056/NEJMoa1804980
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec;377(26):2531–44. doi: https://doi.org/10.1056/NEJMoa1707447
Di Blasi R, Thieblemont C, Haioun C, Sackmann Sala L, Mayaud AC, Diez-Andreu P, et al. Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI. Value Health. 2022;25(12):S79–80. doi: https://doi.org/10.1016/j.jval.2022.09.390
Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html

How to Cite

1.

Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly [Internet]. 2024 Oct. 3 [cited 2025 Oct. 19];154(10):3704. Available from: https://www.smw.ch/index.php/smw/article/view/3704

Share

This work is licensed under a Creative Commons Attribution 4.0 International License.

DOI:: https://doi.org/10.57187/s.3704

[1] Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2023 Sep;153(9):3441. doi: https://doi.org/10.57187/s.3441

[2] Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol. 2024 Jan;42(1):e3241. doi: https://doi.org/10.1002/hon.3241

[3] Duchosal MA, et al. Développements récents en hématologie, Teil 1. Swiss Medical Forum, 2023. doi: https://doi.org/10.4414/fms.2023.09462

[4] Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56. doi: https://doi.org/10.1056/NEJMoa1804980

[5] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec;377(26):2531–44. doi: https://doi.org/10.1056/NEJMoa1707447

[6] Di Blasi R, Thieblemont C, Haioun C, Sackmann Sala L, Mayaud AC, Diez-Andreu P, et al. Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI. Value Health. 2022;25(12):S79–80. doi: https://doi.org/10.1016/j.jval.2022.09.390

[7] Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html